RU2018133157A3 - - Google Patents

Download PDF

Info

Publication number
RU2018133157A3
RU2018133157A3 RU2018133157A RU2018133157A RU2018133157A3 RU 2018133157 A3 RU2018133157 A3 RU 2018133157A3 RU 2018133157 A RU2018133157 A RU 2018133157A RU 2018133157 A RU2018133157 A RU 2018133157A RU 2018133157 A3 RU2018133157 A3 RU 2018133157A3
Authority
RU
Russia
Application number
RU2018133157A
Other versions
RU2018133157A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2018133157A publication Critical patent/RU2018133157A/ru
Publication of RU2018133157A3 publication Critical patent/RU2018133157A3/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/468-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4748Quinolines; Isoquinolines forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542Carboxylic acids, e.g. a fatty acid or an amino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2018133157A 2016-02-22 2017-02-17 Способы применения агонистов fxr RU2018133157A (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662298117P 2016-02-22 2016-02-22
US62/298,117 2016-02-22
US201662420702P 2016-11-11 2016-11-11
US62/420,702 2016-11-11
PCT/IB2017/050912 WO2017145031A1 (en) 2016-02-22 2017-02-17 Methods for using fxr agonists

Publications (2)

Publication Number Publication Date
RU2018133157A RU2018133157A (ru) 2020-03-24
RU2018133157A3 true RU2018133157A3 (ru) 2020-05-29

Family

ID=58191506

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018133157A RU2018133157A (ru) 2016-02-22 2017-02-17 Способы применения агонистов fxr

Country Status (13)

Country Link
US (1) US11229634B2 (ru)
EP (1) EP3419623B1 (ru)
JP (1) JP7053478B2 (ru)
KR (1) KR20180116275A (ru)
CN (2) CN108697704A (ru)
AU (1) AU2017223148B2 (ru)
CA (1) CA3014731A1 (ru)
ES (1) ES2902404T3 (ru)
HK (1) HK1257648A1 (ru)
IL (1) IL261021A (ru)
RU (1) RU2018133157A (ru)
TW (1) TW201735923A (ru)
WO (1) WO2017145031A1 (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3419624T (pt) 2016-02-22 2021-04-07 Novartis Ag Métodos para utilizar agonistas de fxr
WO2017145031A1 (en) 2016-02-22 2017-08-31 Novartis Ag Methods for using fxr agonists
CA3013186A1 (en) * 2016-02-22 2017-08-31 Novartis Ag Methods for using fxr agonists
AR114930A1 (es) 2017-09-12 2020-11-11 Novartis Ag Composición farmacéutica
KR20200094175A (ko) * 2017-11-30 2020-08-06 노파르티스 아게 간 질병의 치료를 위한 fxr 작용제
JP7243959B2 (ja) 2017-12-22 2023-03-22 シチュアン ケルン-バイオテック バイオファーマシューティカル カンパニー リミテッド イソオキサゾール誘導体、その製造方法、及びその使用
KR20220035365A (ko) 2019-07-18 2022-03-22 엔요 파마 인터페론의 부작용을 감소시키는 방법
WO2021144330A1 (en) 2020-01-15 2021-07-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of fxr agonists for treating an infection by hepatitis d virus
JP2024502673A (ja) 2021-01-14 2024-01-22 ウエヌイグレックオ・ファーマ Hbv感染の処置のためのfxrアゴニストとifnの相乗効果
JP2024517181A (ja) 2021-04-28 2024-04-19 ウエヌイグレックオ・ファーマ 組合せ治療としてfxrアゴニストを使用するtlr3アゴニストの効果の強い増強

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9601091L (sv) 1996-03-21 1997-09-22 Joyce Carlson Användning av en proteinsubstans för bindning av steroid-liknande molekyler
US20110034507A1 (en) 2007-07-02 2011-02-10 Smithkline Beecham Corporation Farnesoid x receptor agonists
DK2219652T3 (da) 2007-11-16 2012-08-06 Baylor College Medicine Phospholipidsammensætninger og anvendelser heraf
CU24152B1 (es) 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
PT3419624T (pt) 2016-02-22 2021-04-07 Novartis Ag Métodos para utilizar agonistas de fxr
WO2017145031A1 (en) 2016-02-22 2017-08-31 Novartis Ag Methods for using fxr agonists

Also Published As

Publication number Publication date
JP2019509278A (ja) 2019-04-04
ES2902404T3 (es) 2022-03-28
WO2017145031A1 (en) 2017-08-31
TW201735923A (zh) 2017-10-16
JP7053478B2 (ja) 2022-04-12
US20190046518A1 (en) 2019-02-14
CN108697704A (zh) 2018-10-23
EP3419623B1 (en) 2021-09-29
RU2018133157A (ru) 2020-03-24
US11229634B2 (en) 2022-01-25
HK1257648A1 (zh) 2019-10-25
CA3014731A1 (en) 2017-08-31
AU2017223148A1 (en) 2018-08-30
EP3419623A1 (en) 2019-01-02
IL261021A (en) 2018-10-31
KR20180116275A (ko) 2018-10-24
CN113908158A (zh) 2022-01-11
AU2017223148B2 (en) 2019-07-18

Similar Documents

Publication Publication Date Title
BR122020014835A2 (ru)
BR112019008089A2 (ru)
JP1588790S (ru)
BR122022020382A2 (ru)
JP1573675S (ru)
JP1576865S (ru)
BR112019009269A2 (ru)
CN303543804S (ru)
CN303545102S (ru)
CN303538721S (ru)
CN303538744S (ru)
CN303539498S (ru)
CN303539646S (ru)
CN303539683S (ru)
CN303541243S (ru)
CN303541474S (ru)
CN303542177S (ru)
CN303542399S (ru)
CN303542470S (ru)
CN303542845S (ru)
CN303542968S (ru)
CN303543097S (ru)
CN303543347S (ru)
CN303543693S (ru)
CN303544625S (ru)